Pharma firms operating in India may need to make certain key modifications to their current data privacy programs, including adapting newer controls, to align with the country’s digital personal data protection norms, say legal experts.
India Digital Personal Data Protection Norms: What It May Mean For Clinical Trials, Big Pharma GCCs
Legal heavyweights from Nishith Desai Associates, Anand and Anand, Corporate Law Group and EY partner and national cyber leader outline key compliance aspects that pharma and their global capability centers may need to factor as India moves to strengthen the framework for the protection of digital personal data.
